» Articles » PMID: 39013458

Comprehensive EHMT1 Variants Analysis Broadens Genotype-phenotype Associations and Molecular Mechanisms in Kleefstra Syndrome

Overview
Journal Am J Hum Genet
Publisher Cell Press
Specialty Genetics
Date 2024 Jul 16
PMID 39013458
Authors
Affiliations
Soon will be listed here.
Abstract

The shift to a genotype-first approach in genetic diagnostics has revolutionized our understanding of neurodevelopmental disorders, expanding both their molecular and phenotypic spectra. Kleefstra syndrome (KLEFS1) is caused by EHMT1 haploinsufficiency and exhibits broad clinical manifestations. EHMT1 encodes euchromatic histone methyltransferase-1-a pivotal component of the epigenetic machinery. We have recruited 209 individuals with a rare EHMT1 variant and performed comprehensive molecular in silico and in vitro testing alongside DNA methylation (DNAm) signature analysis for the identified variants. We (re)classified the variants as likely pathogenic/pathogenic (molecularly confirming Kleefstra syndrome) in 191 individuals. We provide an updated and broader clinical and molecular spectrum of Kleefstra syndrome, including individuals with normal intelligence and familial occurrence. Analysis of the EHMT1 variants reveals a broad range of molecular effects and their associated phenotypes, including distinct genotype-phenotype associations. Notably, we showed that disruption of the "reader" function of the ankyrin repeat domain by a protein altering variant (PAV) results in a KLEFS1-specific DNAm signature and milder phenotype, while disruption of only "writer" methyltransferase activity of the SET domain does not result in KLEFS1 DNAm signature or typical KLEFS1 phenotype. Similarly, N-terminal truncating variants result in a mild phenotype without the DNAm signature. We demonstrate how comprehensive variant analysis can provide insights into pathogenesis of the disorder and DNAm signature. In summary, this study presents a comprehensive overview of KLEFS1 and EHMT1, revealing its broader spectrum and deepening our understanding of its molecular mechanisms, thereby informing accurate variant interpretation, counseling, and clinical management.

Citing Articles

Highlighting cardiovascular manifestations of kleefstra syndrome: literature review and clinical insights.

Xie H, He P, Sheng Q, Ma W, Gong Y, Zhang Y BMC Cardiovasc Disord. 2025; 25(1):175.

PMID: 40075254 PMC: 11899436. DOI: 10.1186/s12872-025-04610-1.


EHMT2 as a Candidate Gene for an Autosomal Recessive Neurodevelopmental Syndrome.

Carvalho L, Rzasa J, Kerkhof J, McConkey H, Fishman V, Koksharova G Mol Neurobiol. 2024; .

PMID: 39674972 DOI: 10.1007/s12035-024-04655-x.


Pathogenic variants in KMT2C result in a neurodevelopmental disorder distinct from Kleefstra and Kabuki syndromes.

Rots D, Choufani S, Faundes V, Dingemans A, Joss S, Foulds N Am J Hum Genet. 2024; 111(8):1626-1642.

PMID: 39013459 PMC: 11339626. DOI: 10.1016/j.ajhg.2024.06.009.

References
1.
Dingemans A, Hinne M, Truijen K, Goltstein L, van Reeuwijk J, de Leeuw N . PhenoScore quantifies phenotypic variation for rare genetic diseases by combining facial analysis with other clinical features using a machine-learning framework. Nat Genet. 2023; 55(9):1598-1607. PMC: 11414844. DOI: 10.1038/s41588-023-01469-w. View

2.
Menke L, van Belzen M, Alders M, Cristofoli F, Ehmke N, Fergelot P . CREBBP mutations in individuals without Rubinstein-Taybi syndrome phenotype. Am J Med Genet A. 2016; 170(10):2681-93. DOI: 10.1002/ajmg.a.37800. View

3.
Vermeulen K, de Boer A, Janzing J, Koolen D, Ockeloen C, Willemsen M . Adaptive and maladaptive functioning in Kleefstra syndrome compared to other rare genetic disorders with intellectual disabilities. Am J Med Genet A. 2017; 173(7):1821-1830. DOI: 10.1002/ajmg.a.38280. View

4.
Nachiyappan A, Gupta N, Taneja R . EHMT1/EHMT2 in EMT, cancer stemness and drug resistance: emerging evidence and mechanisms. FEBS J. 2021; 289(5):1329-1351. DOI: 10.1111/febs.16334. View

5.
Rots D, Chater-Diehl E, Dingemans A, Goodman S, Siu M, Cytrynbaum C . Truncating SRCAP variants outside the Floating-Harbor syndrome locus cause a distinct neurodevelopmental disorder with a specific DNA methylation signature. Am J Hum Genet. 2021; 108(6):1053-1068. PMC: 8206150. DOI: 10.1016/j.ajhg.2021.04.008. View